TERN-601 was an experimental daily pill for adults with obesity or overweight [1]. Our comparison of GLP-1 pills and injections covers products consumers can buy. TERN-601 never reached approval. Its sponsor ended development after a liver safety signal.
What the trials found
Participants in the 28-day phase 1 trial lost more weight than placebo at each dose tested [1]. In the 12-week phase 2 trial, estimated average weight losses in the four active groups ranged from 2.2 to 5.0 kg. The placebo group lost an estimated 0.5 kg. The largest average loss occurred in a 500 mg group, and the highest dose did not produce the largest loss.
Why the sponsor stopped development
Three phase 2 participants had substantial rises in the liver enzymes ALT or AST [1]. The enzymes peaked several weeks after the last dose. One event was reported as serious drug-induced liver injury. The authors identified the liver findings as the main reason development stopped.
Liver enzyme elevations prompted scrutiny of this particular drug. Studies of GLP-1 drugs for fatty liver disease test different products and measure different outcomes. The TERN-601 trial cannot estimate liver injury risk for other oral GLP-1 medicines.